Last reviewed · How we verify
Systemic Chemotherapy
Systemic chemotherapy involves the use of drugs to kill cancer cells throughout the body.
Systemic chemotherapy involves the use of drugs to kill cancer cells throughout the body. Used for Treatment of various cancers, including breast cancer, lung cancer, and lymphoma.
At a glance
| Generic name | Systemic Chemotherapy |
|---|---|
| Also known as | MIXED, SOX, none noted, 5-FU, LEUCOVORIN |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | Cytotoxic agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is typically achieved through various mechanisms, including interfering with DNA replication, inhibiting cell division, or inducing apoptosis. The specific mechanism can vary depending on the type of chemotherapy drug used.
Approved indications
- Treatment of various cancers, including breast cancer, lung cancer, and lymphoma
Common side effects
- Nausea and vomiting
- Fatigue
- Hair loss
- Anemia
- Neutropenia
Key clinical trials
- A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- Splenic Artery Infusion Chemotherapy vs Systemic Chemotherapy in Advanced Pancreatic Body/Tail Cancer
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer (NA)
- Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: